FOLH1 and glioblastoma: The study demonstrated that the absorbed dose in the tumour was 100 times higher than in the kidneys, 8.4 times higher than in the liver and 28.7 times higher than in the whole body, and that the radiotracer had a very slow washout in the tumour compared to the other organs in the days following administration [13], generating interest in testing the feasibility of using PSMA-617-based targeted therapy with α/β-emitters for the treatment of recurrent GBM patients.